Eyre B L K D, Eadie M J, van Driel M L, Ross-Lee L, Hollingworth S A
School of Pharmacy, The University of Queensland, Woolloongabba, Qld, Australia.
School of Medicine, The University of Queensland, Herston, Qld, Australia.
Acta Neurol Scand. 2017 Aug;136(2):155-159. doi: 10.1111/ane.12727. Epub 2017 Jan 16.
This study examined the use of triptan derivatives in Australia between 1997 and 2015, based on a national drug reimbursement database, and compared patterns of use with available international data.
We obtained publically available data on the number of prescriptions for triptans marketed in Australia (sumatriptan, eletriptan, rizatriptan, zolmitriptan, naratriptan). Dispensed use was measured as defined daily dose (DDD per 1000 population per day) for Australia's concessional beneficiaries (low-income earners, people with disabilities, and seniors).
Total triptan use increased at an average annual rate of 112% over the 18-year period. Sumatriptan was the preferred triptan throughout (average annual increase 45%). Zolmitriptan and naratriptan use peaked in 2004, then decreased. Rizatriptan and eletriptan became available in 2010. There were 3.2-fold and 5.9-fold annual increases in their use from 2011 to 2105. There was some evidence suggesting that pattern of triptan use in concessional beneficiaries probably reflected pattern of overall triptan use in Australia.
The use of triptan derivatives in Australia per head of population for treating migraine attacks continued to increase over the 18-year period studied, with use of recently introduced derivatives more than substituting for decreased use of older triptans. This suggests that the available treatments of migraine attacks had achieved what were considered less than adequate therapeutic outcomes.
本研究基于国家药品报销数据库，对1997年至2015年澳大利亚曲坦类衍生物的使用情况进行了调查，并将其使用模式与国际现有数据进行了比较。
我们获取了澳大利亚市场上销售的曲坦类药物（舒马曲坦、依立曲坦、利扎曲坦、佐米曲坦、那拉曲坦）的处方数量的公开数据。以澳大利亚特惠受益人群（低收入者、残疾人和老年人）的限定日剂量（每千人口每日的DDD）来衡量药物的配给使用情况。
在这18年期间，曲坦类药物的总使用量以年均112%的速度增长。舒马曲坦一直是首选的曲坦类药物（年均增长45%）。佐米曲坦和那拉曲坦的使用量在2004年达到峰值，随后下降。利扎曲坦和依立曲坦于2010年上市。从2011年到2015年，它们的使用量每年分别增长3.2倍和5.9倍。有证据表明，特惠受益人群中曲坦类药物的使用模式可能反映了澳大利亚曲坦类药物的总体使用模式。
在研究的18年期间，澳大利亚用于治疗偏头痛发作的曲坦类衍生物人均使用量持续增加，新推出的衍生物的使用量足以弥补旧曲坦类药物使用量的下降。这表明现有的偏头痛发作治疗方法并未达到被认为足够的治疗效果。
